Exelixis
EXEL
#1758
Rank
A$17.33 B
Marketcap
A$64.39
Share price
1.36%
Change (1 day)
18.72%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): A$3.63

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$3.60. In 2023 the company made an earnings per share (EPS) of A$0.99 an increase over its 2022 EPS that were of A$0.86.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$3.63
2023A$0.9914.61%
2022A$0.86-22.97%
2021A$1.12100%
2020A$0.56-65.09%
2019A$1.60-53.91%
2018A$3.48333.96%
2017A$0.80-260.61%
2016A-$0.50-58.75%
2015A-$1.21-42.45%
2014A-$2.105.3%
2013A-$2.00

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
A$5.44 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
A$5.61 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$11.49 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$4.49 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$19.71 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
A$15.79 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$2.60-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
A-$5.55-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.27-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA